% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • duncecap Feb 13, 2014 6:01 PM Flag

    How much OS benefit is enough?

    Based on what we saw in the Zaltrap and Dasatinib trials, its seem reasonable to expect median OS in the control arm to come in at around 22 months. Based on this, I have an estimated median OS of 25 months in the custirsen arm. If I'm right, this seems like it may be too close to declare victory, as the closest successful trial I've come across is the provenge P3 (25.8 months vs 21.7 months).

    Any insight from those more statistically inclined?

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.00-0.0200(-1.96%)May 26 3:59 PMEDT